ClinicalTrials.gg
CompletedNCT04656795Updated May 15, 2023

PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function

A Phase 1 interventional study of MT-7117 in Renal Impairment and Normal Renal Function, sponsored by Mitsubishi Tanabe Pharma America Inc.. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-15.

Sponsored by Mitsubishi Tanabe Pharma America Inc. (part of Tanabe Pharma Corporation) · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Dec 2021, 4 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.

Enrollment
76th of 113
32 · median 42
Started
2020
with 4 others
Phase 1
54 of 139
1 open now
Registered
102nd of 139
by date

Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 76th largest by enrollment of the 113 interventional ones that give a count, is one of 5 that started in 2020, is one of 54 in phase 1, and was the 102nd registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Renal Insufficiency with a site in Germany, or all of them as a file.
02

Study summary

This is an open-label, non randomised, single-dose, study in male and female subjects with renal impairment (severe and if required mild \& moderate) compared to male and female subjects with normal renal function.

03

Conditions studied

  • Renal Impairment
  • Normal Renal Function

Keywords

  • PK Study in subjects with renal impairment (severe and if required mild & moderate) vs. subjects with normal renal function
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A subject will be eligible for enrolment in the study if ALL of the following criteria apply:

For Groups 1, 2, 3 and 4

  1. Subject is able to provide written to participate in this study after reading the participant information sheet and Informed Consent Form (ICF) and after having the opportunity to discuss the study with the Investigator or designee.
  2. Male or female subjects, ≥ 18 to 80 years of age (inclusive), at the time of signing the ICF.
  3. In the Investigator's opinion, subject is able to understand the nature of the study and all risks involved with participation in the study and willing to cooperate and comply with all Protocol restrictions and requirements.
  4. Subjects must weigh at least 50 kg (110 pounds) and have a 18 to 35 kg/m2 both inclusive at Screening and on Day -1.
  5. The subject's vital signs must be within the reference range for their age at Screening and on Day 1. Subjects must have rested for at least 5 minutes in a supine position prior to collecting blood pressure and pulse. In subjects with normal renal function, normal blood pressure is considered in the range of 90 to 145 mmHg for systolic blood pressure (SBP) and 50 to 95 mmHg for diastolic blood pressure (DBP). In subjects with renal impairment, normal blood pressure is considered in the range of 90 to 179 mmHg for SBP and 50 to 105 mmHg for DBP. Pulse rate should be between 50 to 100 beats per minutes.
  6. Female subjects must not be lactating and must have a negative serum pregnancy test at Screening and on Day 1.
  7. Female subjects of child bearing potential and male subjects with a partner of child bearing potential must agree to use 2 effective methods of (in female subjects, one method must be highly effective.

For Group 1 (Subjects with Normal Renal Function)

  1. Subjects must have an absolute of ≥ 90 mL/min, as determined by the MDRD equation, multiplied by the individual BSA according to the DuBois \& DuBois equation and divided by 1.73 m2 at Screening and confirmed at Day 1 (admission to the study centre).
  2. Subjects must be in good health and free from illness or disease in the opinion of the Investigator based upon the results of medical history, physical examination, clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis), vital signs and a 12 lead (ECG) at Screening and Day -1.
  3. Subjects with normal renal function (Group 1) will be matched in pairs by race, age (± 10 years of subject in Group 4), weight (± 10 kg of the subject in Group 4), gender and smoking status to subjects with severe renal impairment (Group 4).

For Groups 2 to 4 (Subjects with Renal Impairment)

  1. Subjects must have stable renal impairment based on medical history, physical examination and clinical laboratory results. Stable renal impairment is defined as no clinically significant change in an eGFR within 3 months or longer prior to study Screening, as determined by the Investigator.
  2. Subjects with renal impairment must have the following absolute eGFR values as determined by the MDRD equation, multiplied by the individual BSA according to the DuBois \& DuBois equation and divided by 1.73 m2 at Screening and confirmed at Day 1 (admission to the study centre) Group 2: Mild renal impairment must have an absolute eGFR of ≥ 60 to \< 90 mL/min Group 3: Moderate renal impairment must have an absolute eGFR of ≥ 30 to \< 60 mL/min Group 4: Severe renal impairment must have an absolute eGFR of \< 30 mL/min; not on dialysis
  3. Subjects must have acceptable clinical conditions in the opinion of the Investigator based upon the results of medical history, physical examination, clinical laboratory tests (biochemistry, haematology, coagulation and urinalysis), vital signs and a 12 lead ECG at Screening and Day -1.
  4. The age of subjects in Groups 2 and 3 must not be more than 10 years younger than the youngest subject in Group 1 or more than 10 years older than the oldest subject in Group 1. The weight of subjects in Groups 2 and 3 must not be more than 20% lighter than the lightest subject in Group 1 or more than 20% heavier than the heaviest subject in Group 1.
  5. Subjects with mild renal impairment (Group 2) and moderate renal impairment (Group 3) will be matched by race, age, weight and gender to subjects in Group 1 (age and weight are to be matched as per inclusion criterion 4 above. It is not necessary to match subjects between Groups 2 and 3 and Group 1 in pairs, but there must be the same number of each gender and each race in each of Groups 2 and 3 as there are in Group 1).

Exclusion criteria

Exclusion Criteria:

  • A subject will NOT be eligible for this study if ANY of the following criteria apply:

For Groups 1, 2, 3 and 4

  1. Subjects who have a known to MT-7117 or related compounds (or relevant ). Subjects who have a history of clinically significant hypersensitivity, intolerance, allergy or anaphylaxis to any drug compound, food or other substance unless approved by the Investigator and the Sponsor.
  2. Subjects who are currently on dialysis.
  3. Subjects who have any active (including melanoma but excluding basal cell carcinoma) or history of significant malignancy (including melanoma).
  4. Subjects who have previously participated in a study involving MT-7117 within 6 months prior to the first dose of Medicinal Product (IMP) and/or subjects who have previously taken any other investigational drug within 2 months or 5 half-lives prior to the first dose of IMP, whichever is longer.
  5. A history or presence of clinically significant neurological, haematological, psychiatric, gastrointestinal (including cholecystectomy), pulmonary or hepatic disease or other condition (with the exception of renal insufficiency for Groups 2 to 4) known to interfere with the absorption, distribution, metabolism or excretion of drugs or any condition which could place the subjects at increased risk as determined by the Investigator.
  6. Clinically significant 12-lead abnormalities, including subjects with interval using Fridericia's formula (QTcF) of > 450 ms (male) and > 470 ms (female), at Screening or Day -1, confirmed by repeat assessment.
  7. Subject takes non-permitted concomitant medication within 28 days (or 5 half lives of the drug, whichever is longer) of dosing on Day 1. Subjects with normal renal function are restricted from use of any concomitant medications unless discussed and agreed with the Sponsor. For renal impaired subjects, prescribed medication or over the counter (OTC) medication for treating underlying disease states or chronic medical conditions or disorders related to renal impairment are permitted as described in the protocol. If subjects with renal impairment are on any medication not listed in the protocol, this must be discussed with the Sponsor on a case-by-case basis, prior to the subject's inclusion in the study.
  8. Subjects who have a positive drug screen at Screening or Day 1 (admission to the study centre), unless the positive drug screen is due to prescription drug use that is approved by the Investigator and the Sponsor.
  9. Subjects who have a positive (HIV) antibody at Screening. Consent and counselling for this procedure will be performed according to the site's Standard Operating Procedures.
  10. Subjects who have a positive test for surface antigen (HBsAg), hepatitis B core antibody (HBcAb) or antibody (HCVAb) at Screening.
  11. Acute illness or infection, minor surgical procedures or trauma from within 2 weeks before Screening until administration of study drug.
  12. Subjects who have a history of kidney, other organ or bone marrow transplant.
  13. Subjects who have a history of major surgery within 3 months before Day 1.
  14. Subjects who have a history of long QT syndrome or cardiac brady-tachy-arrhythmia.
  15. Donation of 1 or more units of blood (≥ 450 mL) in the 3 months prior to Screening or plasma in the 7 days prior to Screening or in the 6 weeks prior to Screening or intention to donate blood within 3 months after the final follow-up assessment.
  16. Subjects who have consumed liquorice, grapefruit or grapefruit juice, orange or their associated products, within 7 days prior to study treatment on Day 1.
  17. Subjects who are smokers or use tobacco or nicotine containing products (snuff, chewing tobacco, cigarettes, cigars, pipes, e-cigarettes or nicotine replacement products) and currently smoke more than 10 cigarettes or equivalent per day or are unable or unwilling to stop from 4 hours pre-dose until 6 hours post dose.
  18. Subjects who are not willing to abstain from consumption of caffeine and methylxanthine (e.g., coffee, tea, cola, energy drinks or chocolates) in the 36 hours before Day 1 until completion of the post-treatment assessments on Day 4 and in the 36 hours before the Follow-up/EoS Visit on Day 8.
  19. Subjects who regularly, or on average, drink more than 21 units (168 g) for males or 14 units (112 g) for females, of alcohol per week (1 unit is equivalent to 8g of alcohol).
  20. Subjects with any other condition or reason that, in the opinion of the Investigator or Sponsor, would make the subject unsuitable for enrolment.
  21. Subjects who test positive for Coronavirus Disease 2019 at Screening or Day -1.
  22. Subject with the presence of a skin lesion suspicious for dysplastic naevus or a history of proven dysplastic naevus.

Group 1 (Subjects with Normal Renal Function):

(1) Subjects with (AST), alanine aminotransferase (ALT), gamma-glutamyl transpeptidase (GGT) or total level (TBL) > 1.5 times (ULN) during Screening or at Day 1.

For Groups 2, 3 and 4 (Subjects with Renal Impairment)

  1. Use of concurrent medications, which affect the such as cephalosporin antibiotics, ascorbic acid, trimethoprim, cimetidine or quinine for at least 28 days prior to Day 1 (or 5 half-lives of the drug, whichever is longer).
  2. Subject who has renal disease secondary to malignancy.
  3. Subjects with acute renal failure.
  4. Subject with any of the liver function test (AST, ALT, ALP and TBL) out of the following range (TBL > 1.5 × ULN, ALT and AST > 2 × ULN and ALP > 3 × ULN) at Screening or Day -1.
  5. Subjects have serum albumin \< 30 g/L and \< 8 g/dL
  6. Subject has not been on a stable dose of concomitant medications for the previous 28 days and/or has started new medications to treat concurrent chronic conditions in the previous 28 days (or 5 half lives of the drug, whichever is longer) prior to IMP dosing. Minor dose adjustments to the subject's regular medication may be allowed up to 14 days prior to IMP dosing after consultation with the Sponsor. This medication regimen should not change whilst the subject is enrolled in the study.
  7. Any clinically significant abnormalities, other than those associated with the subject's degree of renal impairment, in biochemistry, haematology, coagulation and urinalysis results as judged by the Investigator and the Sponsor.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Subjects with severe renal impairment

    Drug: MT-7117

  • Experimental
    Subjects with normal renal function

    Drug: MT-7117

  • Experimental
    Subjects with moderate renal impairment

    Drug: MT-7117

  • Experimental
    Subjects with mild renal impairment

    Drug: MT-7117

Interventions

  • MT-7117

    Also known as: dersimelagon

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax) of MT-7117

    Time frame: Day 1 to 4

  2. Area under the plasma concentration time curve from time zero to the last quantifiable concentration (AUC0-last) of MT-7117

    Time frame: Day 1 to 4

  3. Area under the plasma concentration time curve from time zero to infinity (AUC0-∞) of MT-7117

    Time frame: Day 1 to 4

Secondary outcomes

  1. Safety and tolerability as measured by incidence of Treatment emergent adverse events

    Time frame: Day -1 to Day 8

  2. Time to maximum plasma concentration (tmax) of MT-7117

    Time frame: Day 1 to 4

  3. Apparent elimination half-time of MT-7117 in plasma (t1/2)

    Time frame: Day 1 to 4

  4. Apparent oral clearance (CL/F) of MT-7117in plasma

    Time frame: Day 1 to 4

  5. Apparent volume of distribution during the terminal phase (Vz/F) of MT-7117in plasma

    Time frame: Day 1 to 4

  6. Unbound fraction (fu) of MT-7117 in plasma

    Time frame: Day 1 to 4

  7. Maximum observed unbound plasma concentration (Cmax,u) of MT-7117 of MT-7117

    Time frame: Day 1 to 4

  8. Area under the unbound plasma concentration time curve from time zero to the last quantifiable concentration (AUC0-last, u) of MT-7117

    Time frame: Day 1 to 4

  9. Area under the unbound plasma concentration time curve from time zero to infinity (AUC0-∞, u)of MT-7117

    Time frame: Day 1 to 4

07

Study locations

1 site
  • Clinical Research Services (CRS) Kiel GmbH
    Kiel, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Dec 2021, 12 months.

Of 212 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 12 months is above that.

Counting every sponsor, half of 230 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 23, 2020
First posted
Dec 7, 2020
StartActual
Dec 2, 2020
Primary completionActual
Dec 4, 2021
CompletionActual
Dec 9, 2021
Last update
May 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04656795
Responsible party
Sponsor
First posted
Dec 7, 2020
Start date
Dec 2, 2020
Primary completion
Dec 4, 2021
Completion
Dec 9, 2021
Last update
May 15, 2023

Study contacts

Head of Medical Science
study director · Mitsubishi Tanabe Pharma America Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dersimelagon

Start the discussion